Skip to main content
Erschienen in: Neuroethics 2/2014

01.08.2014 | Original Paper

Will There Ever Be a Drug with No or Negligible Side Effects? Evidence from Neuroscience

verfasst von: Sylvia Terbeck, Laurence Paul Chesterman

Erschienen in: Neuroethics | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Arguments in the neuroenhancement debate are sometimes based upon idealistic scenarios involving the assumption of using a drug that has no or negligible side effects. At least it is often implicitly assumed – as technology and scientific knowledge advances - that there soon will be a drug with no or negligible side effects. We will review evidence from neuroscience, complex network research and evolution theory and demonstrate that - at least in terms of psychopharmacological intervention – on the basis of our understanding of brain function it seems inconceivable that there ever will be a drug that has the desired effect without undesirable side effects. We will illustrate this by reference to enhancing edge detection in V2 in monkeys and demonstrate that even for this localised single neuron coded function there would be numerous side effects. Taking the more realistic case of pharmacological enhancement that is inevitably associated with side effects will change consequentialist arguments for neuroenhancement and have implications for the conception of autonomy, specifically in the case of performance enhancement. We conclude that a neuroethics debate that aims to inform policy decisions should take these findings into account. We hope that our article will precipitate more interdisciplinary research in neuroscience and philosophy.
Fußnoten
1
(Personal conversation: Neuroenhancement conference University of Mainz, Germany, 2011).
 
2
President’s Council in Bioethics.
 
Literatur
1.
Zurück zum Zitat Synofzki, M., and T.E. Schlaepfer. 2008. Stimulating personality: Ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes. Biotechnological Journal 3: 1511–1520. Synofzki, M., and T.E. Schlaepfer. 2008. Stimulating personality: Ethical criteria for deep brain stimulation in psychiatric patients and for enhancement purposes. Biotechnological Journal 3: 1511–1520.
2.
Zurück zum Zitat Elliott, C. 1999. A philosophical disease. Bioethics, culture, and identity. New York: Routledge. Elliott, C. 1999. A philosophical disease. Bioethics, culture, and identity. New York: Routledge.
3.
Zurück zum Zitat Kramer, P. 1993. Listening to Pronzac. New York: Viking. Kramer, P. 1993. Listening to Pronzac. New York: Viking.
4.
Zurück zum Zitat Repantis, D., P. Schlattmann, O. Laisney, and I. Heuser. 2009. Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis & Praxis 6: 139–174.CrossRef Repantis, D., P. Schlattmann, O. Laisney, and I. Heuser. 2009. Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis & Praxis 6: 139–174.CrossRef
5.
Zurück zum Zitat Kirsch, I., and B.J. Deacon. 2008. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. Public Library of Science Medicine 5: 26. Kirsch, I., and B.J. Deacon. 2008. Initial severity and antidepressant benefits: A meta-analysis of data submitted to the food and drug administration. Public Library of Science Medicine 5: 26.
6.
Zurück zum Zitat Savulescu, J., A. Sandberg, and G. Kahane. 2011. Well-being and enhancement. In Enhancing human capacities, ed. J. Savulescu, R. ter Meulen, and G. Kahane. Oxford: Wiley Blackwell. Savulescu, J., A. Sandberg, and G. Kahane. 2011. Well-being and enhancement. In Enhancing human capacities, ed. J. Savulescu, R. ter Meulen, and G. Kahane. Oxford: Wiley Blackwell.
7.
Zurück zum Zitat Dees, R.H. 2007. Better brains, better selves? The ethics of neuroenhancement. Kennedy Institute of Ethics Journal 17(4): 371–396.CrossRef Dees, R.H. 2007. Better brains, better selves? The ethics of neuroenhancement. Kennedy Institute of Ethics Journal 17(4): 371–396.CrossRef
8.
Zurück zum Zitat Berghmans, R., R. ter Meulen, A. Malizia, and R. Vos. 2011. Scientific, ethical, and social issues in mood enhancement. In Enhancing human capacities, ed. J. Savulescu, R. ter Meulen, and G. Kahane. Oxford: Wiley Blackwell. Berghmans, R., R. ter Meulen, A. Malizia, and R. Vos. 2011. Scientific, ethical, and social issues in mood enhancement. In Enhancing human capacities, ed. J. Savulescu, R. ter Meulen, and G. Kahane. Oxford: Wiley Blackwell.
9.
Zurück zum Zitat Sahakian, B., and S. Morein-Zamir. 2007. Professor’s little helper. Nature 450(7173): 1157–1159.CrossRef Sahakian, B., and S. Morein-Zamir. 2007. Professor’s little helper. Nature 450(7173): 1157–1159.CrossRef
10.
Zurück zum Zitat Douglas, T. 2011. Moral enhancement. In Enhancing human capacities, ed. J. Savulescu, R. ter Meulen, and G. Kahane. Oxford: Wiley Blackwell. Douglas, T. 2011. Moral enhancement. In Enhancing human capacities, ed. J. Savulescu, R. ter Meulen, and G. Kahane. Oxford: Wiley Blackwell.
11.
Zurück zum Zitat Palfai, T., and H. Jankiewicz. 1997. Drugs and human behaviour. New York: Superstock. Palfai, T., and H. Jankiewicz. 1997. Drugs and human behaviour. New York: Superstock.
12.
Zurück zum Zitat Bullmore, E., and O. Sporns. 2009. Complex brain networks: Graph theoretical analysis of structural and functional systems. Nature Reviews Neuroscience 10: 186–198.CrossRef Bullmore, E., and O. Sporns. 2009. Complex brain networks: Graph theoretical analysis of structural and functional systems. Nature Reviews Neuroscience 10: 186–198.CrossRef
14.
Zurück zum Zitat Von der Heydt, R., H. Zhou, and H.S. Friedman. 2000. Representation of stereoscopic edges in monkey visual cortex. Vision Research 40: 1955–1967.CrossRef Von der Heydt, R., H. Zhou, and H.S. Friedman. 2000. Representation of stereoscopic edges in monkey visual cortex. Vision Research 40: 1955–1967.CrossRef
15.
Zurück zum Zitat Disney, A.A., K.V. Domakonda, and C. Aoki. 2006. Differential expression of muscarinic acetylcholine receptors across excitatory and inhibitory cells in visual cortical areas V1 and V2 of the macaque monkey. The Journal of Comparative Neurology 499. Disney, A.A., K.V. Domakonda, and C. Aoki. 2006. Differential expression of muscarinic acetylcholine receptors across excitatory and inhibitory cells in visual cortical areas V1 and V2 of the macaque monkey. The Journal of Comparative Neurology 499.
16.
Zurück zum Zitat Spencer, D.G., E. Horvath, and J. Traber. 1986. Direct autodiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain. Brain Research 380: 59–68.CrossRef Spencer, D.G., E. Horvath, and J. Traber. 1986. Direct autodiographic determination of M1 and M2 muscarinic acetylcholine receptor distribution in the rat brain. Brain Research 380: 59–68.CrossRef
17.
Zurück zum Zitat Tang, Y.P., E. Shimizu, G.R. Dube, C. Rampon, G.A. Kerchner, and M. Zhuo. 1999. Genetic enhancement of learning and memory in mice. Nature 401: 63–69.CrossRef Tang, Y.P., E. Shimizu, G.R. Dube, C. Rampon, G.A. Kerchner, and M. Zhuo. 1999. Genetic enhancement of learning and memory in mice. Nature 401: 63–69.CrossRef
18.
Zurück zum Zitat Cooke, S.F., and T.V.P. Bliss. 2003. The genetic enhancement of memory. Cell and Molecular Life Science 60: 1–5.CrossRef Cooke, S.F., and T.V.P. Bliss. 2003. The genetic enhancement of memory. Cell and Molecular Life Science 60: 1–5.CrossRef
Metadaten
Titel
Will There Ever Be a Drug with No or Negligible Side Effects? Evidence from Neuroscience
verfasst von
Sylvia Terbeck
Laurence Paul Chesterman
Publikationsdatum
01.08.2014
Verlag
Springer Netherlands
Erschienen in
Neuroethics / Ausgabe 2/2014
Print ISSN: 1874-5490
Elektronische ISSN: 1874-5504
DOI
https://doi.org/10.1007/s12152-013-9195-7

Weitere Artikel der Ausgabe 2/2014

Neuroethics 2/2014 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.